Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar;43(3):528-530.
doi: 10.1111/liv.15513.

The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma

Giuseppe Cabibbo  1 , Julien Edeline  2
Affiliations
Editorial

The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma

Giuseppe Cabibbo et al. Liver Int. 2023 Mar.
No abstract available

Keywords: competing risk; immune checkpoint inhibitors; immunotherapy; liver cancer; overall survival; prognosis; progression; surrogacy; tyrosine kinase inhibitors.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598-1606.
    1. Garuti F, Neri A, Avanzato F, et al. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2021;41(3):585-597.
    1. Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77(1):128-139.
    1. Edeline J, Meyer T, Blanc JF, Raoul JL. New challenges facing systemic therapies of advanced HCC in the era of different first-line immunotherapy-based combinations. Cancers (Basel). 2022;14(23):5868.
    1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345-1362.

LinkOut - more resources